« Drug R&D Spending Now Down (But Look at the History) |
| Avastin At the FDA Today: Passion Should Lose »
June 29, 2011
For Responsible Stem Cell Reporting. . .
. . .you either have to go to the specialty press, or (sometimes) to the last couple of paragraphs of a mainstream article. For several years now, it's been hard to think of any medical field that's been more relentlessly overhyped than stem cell therapy (a worst-case example was its appearance in the 2004 elections, courtesy of the ever-reliable John Edwards?).
FiercePharma has a good short look at an article in Time that is much more well-balanced than most, but still has some of the usual problems. And don't get me wrong - I think that stem cells are an exciting area of research, an excellent thing to be investigating, and could quite possibly lead to some wonderful results. But not next week. And not without a few billion dollars, most likely. Anyone who tells you otherwise is, to my mind, to be regarded with suspicion.
+ TrackBacks (0) | Category: Press Coverage
POST A COMMENT
- RELATED ENTRIES
- Traveling Interruption
- More Good PD-1 News in Cancer
- Novartis's Stealthy Headcount Reductions
- Sydney Brenner on the State of Science
- A Bit More Realism in Consulting
- Out to Illinois
- A Call To Rein In Phase III Trials
- Computational Nirvana